TEMEKA STOKER: Open Payments
NPI 1427574458 · FORT WORTH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,244 in 64 payments from 19 companies in 2025. Trend: 2023 $571 · 2024 $1,205 · 2025 $1,244
Food & beverage: $1,244
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 13 | $223 |
| Novo Nordisk Inc | 8 | $162 |
| Lilly USA, LLC | 10 | $156 |
| GENZYME CORPORATION | 1 | $122 |
| Astellas Pharma US Inc | 5 | $95 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $93 |
| ABBVIE INC. | 3 | $62 |
| SANOFI-AVENTIS U.S. LLC | 3 | $62 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Lundbeck LLC | 3 | $41 |
Products named: JARDIANCE, AIRSUPRA, FABRAZYME, Veozah, REXULTI, MOUNJARO, TZIELD, Ozempic.
Industry payments across TX — which companies pay providers there.
